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Abstract
The study objective was to evaluate the effect of the California Maternal Quality Care 
Collaborative (CMQCC) initiative, as implemented in a southwestern U.S. tertiary hospital, on 
associated patient costs and outcomes. Using a quasi-experimental study design, we collected 
existing data (cost and patient outcomes) comparing two six–month periods at the baseline and 
one–year follow-up. Following descriptive statistics, Chi-square tests and t-tests were used to 
compare categorical and continuous variables, respectively. One hundred and eighty-nine 
women met the inclusion criteria for the study (93 and 96 women in the baseline and follow-up 
period, respectively). There was no significant difference in maternal health outcomes between 
both periods. However, there was a significant difference for newborns with almost 90% 
(95%CI=0.06–0.92; p=0.027) reduction in stillbirths in the follow-up period. There was also a 
significant reduction in the days between discharge and follow-up appointments (p<0.01). 
Importantly, the initiative bears no additional financial burden on patients, as hospitalisation 
cost was unchanged.
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Impact statement
 What is already known on this subject? In 2013, the California Maternal Quality 
Care Collaborative (CMQCC) set up a task force to develop guidelines for managing 
patients with preeclampsia based on global best practices. A previous study showed that 
despite system-level implementation challenges, the initiative led to significant increase 
in blood pressure treatments within one–hour and reduced severe maternal morbidity.
 What do the results of this study add? This study follows patients from admission, 
beyond the one–hour post-treatment and into the post-partum phase, to understand if 
outcomes of the initiative extend beyond the admission. While the study findings do not 
show any statistically significant difference in readmission before and after the 
initiative, nor any marked difference in maternal outcomes, it shows a significant 
difference in the prevalence of stillbirths at no additional cost to the patient.
 What are the implications of these findings for clinical practice and/or further 
research? Based on these findings, there is a case for scaling-up the initiative as in 
addition to its evidenced improvements in maternal outcomes; it is effective in 
improving newborn health outcomes at no additional cost. Further research, using larger 
sample size and exploring different care levels would be useful to verify these findings.
Key words: Pre-eclampsia; hypertension; pregnancy; safety; quality collaborative; 
quality improvement
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Introduction
Globally, preeclampsia is one of the leading causes of pregnancy-related morbidity and 
mortality (Say et al. 2014). The condition is associated with increased risks of preterm delivery, 
intra-uterine growth restriction, placental abruption and perinatal mortality (Conde-Agudelo et 
al. 2000; Zhang et al. 2000; Goldenberg et al. 2008; Ananth and Basso 2010). Some authors 
have described pre-eclampsia as a “sentinel marker” for women who will develop chronic 
cardiovascular conditions following delivery (Irgens et al. 2001). Women with pre-eclampsia 
have an increased risk of future hypertension, ischemic heart disease and stroke (Bramham et 
al. 2013). In the United States, with an estimated prevalence of 3.8% in 2010 (Ananth et al. 
2013), pre-eclampsia is responsible for 17% of all maternal deaths that occur. However, 50% – 
70% of such deaths are deemed preventable (MCAH 2012).
In 2013, the California Maternal Quality Care Collaborative (CMQCC) set up a task force 
made up of a multi-disciplinary team of experts, working in both high and low-volume 
obstetric units. They were tasked to develop tools and guidelines for managing patients with 
preeclampsia based on global best practices in diagnosis and management of preeclampsia 
(CMQCC 2013). The quality improvement initiative required early detection of preeclampsia 
with blood pressure (BP) confirmation within 15 – 20 minutes, if BP>160/110 mmHg, provider 
notification, the institution of treatment (based on evidence-based algorithms) within one–hour 
of BP confirmation including seizure prophylaxis with Magnesium Sulphate (Figure 1). Further 
recommendations include a follow-up appointment within 3 – 7 days if anti-hypertensive 
medication was used during labour and delivery or postpartum or within 7 – 14 days if no anti-
hypertensive medication was used. The initiative also requires standardised patient education 
(CMQCC 2013).
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Previous studies that assessed the effectiveness of the initiative in reducing severe maternal 
morbidity (SMM) were based on a process indicator of time to institute treatment and 
immediate outcome indicator of the persistence of severe maternal morbidity one–hour after the 
institution of treatment (Shields et al. 2015; 2017). However, no study had explored the effect 
of the initiative on the cost of care and outcomes that occur beyond this one–hour post-
treatment phase, despite the known fact that complications of preeclampsia can extend even 
beyond delivery and into the six–week post-partum period (Matthys et al. 2004). Our study 
objective was to evaluate the effectiveness of the CMQCC initiative as implemented in a 
tertiary hospital on associated patient costs and outcomes during the intrapartum and post-
partum periods.
Materials and methods
A quasi-experimental design was used for this study. This design has been selected because it 
was not logistically feasible and unethical to conduct a randomised controlled trial, which is 
generally regarded as the “gold standard” of causal research design (Morgan et al. 2000; Harris et 
al. 2006), since women with preeclampsia cannot be denied of care they require upon 
presentation.
Study setting
This study was conducted in St. Joseph’s Hospital and Medical Centre (SJHMC) hospital, 
which is managed by a non-profit organisation, Dignity Health. In 2014, the organisation 
embedded the CMQCC pre-eclampsia initiative as practice across all its hospitals including 
SJHMC, where about 5,000 births occur annually.
Data collection
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Existing secondary data was mined for this research with coded data from a six–month pre-
collaborative baseline period compared to prospectively reported outcomes of a six–month 
follow-up period, one–year after the CMQCC implementation. The coded intrapartum data was 
mined from the patient database (Midas®) and additional post-partum data collected from patient 
records (as this could not be mined in Midas®). Microsoft Excel (Microsoft Corporation, 
Redmond, California, USA) was used as a repository for the secondary data, collating the data 
in such a way it was easily retrievable.
All women, 18 years and above, who had conditions that could be classed under the relevant 
International Classification of Diseases (ICD)-10 codes for pre-eclampsia as recommended by 
experts (Callaghan et al. 2014) and captured on the Midas platform (Supplemental file 1) and 
who presented in the hospital within either study phase (baseline and follow-up) were included 
in the study. 
 
Data on the pregnancy characteristics and relevant pre-existing conditions, intrapartum care and 
outcomes as well as outcomes reported during the post-partum period was collected. Using a 
unique patient medical record number (anonymised), we gathered pregnancy-related data 
focused on gestational age on admission (term vs. pre-term), number of foetuses (singleton vs. 
multiple gestation), delivery method, admission date, delivery date and discharge date (the 
latter three variables were used to estimate admission to delivery and admission to discharge 
period). 
Also, we collected data on pre-existing conditions such as obesity and chronic hypertension. 
Intrapartum care data included data on the course of treatment, including the time and date for 
the initial episode of BP trigger (>160/100mmHg) and treatment regimen given to the patients. 
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The data on any complications of pre-eclampsia which had been reported during the 
hospitalisation, included eclampsia, stroke, post-partum haemorrhage, pulmonary oedema, 
renal insufficiency (Creatinine >1.1mg/dL or double in a woman with already high creatinine) 
and liver injury (Twice normal high of Aspartate transaminase [AST]=68IU/L and Alanine 
transaminase [ALT]=110 IU/L) were also collected. In addition, we collected data on the cost 
of intrapartum care (only direct hospitalisation costs that included hospitalisation stay, 
medicines, and provider costs were included) and the payer for the care received 
(Self/Commercial/Medicaid/Medicare/Others). Post-partum period data captured included data 
on follow-up appointment time frame, BP after delivery, readmission history in the hospital for 
post-partum pre-eclampsia.
We used a comprehensive standardised operating procedure manual and ethical guidelines to 
support data collection. To quality-assure the data collection process, the investigators were 
competent in quantitative research with previous experience and significant training as well as 
trained in good clinical practice and data management, which was recently updated. Also, data 
was rechecked for completeness, accuracy and to avoid any errors which could bias analysis.
Data analysis
Following data collation in Microsoft Excel, the completed data sheet was exported to STATA 
13.0 SE (Stata-Corp., College Station, Texas, USA), for analysis. Cost and outcome in a six–
month pre-collaborative baseline were compared to the prospectively reported outcomes of the 
six–month follow-up period, one year after implementation of the initiative. The rationale for the 
choice of this one–year gap between the baseline and follow-up in the research is based on the 
85% uptake of the protocol at this point. We argued that such a high percentage uptake would 
make outcome attributed to the initiative more sensible. 
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Descriptive statistics with percentages were used to describe the demographic characteristics of 
the women included in the study. Chi-square test was used in comparing the proportion of 
outcomes at baseline with the one–year follow-up period, as this was categorical data. For cost, 
which is a continuous variable, the Student t-test comparison of two means was used for the 
analysis. Results were presented in tables with odds ratio, confidence intervals and p-values. A 
significance level of p<0.05 was used to confirm if there were any statistically significant 
differences in costs and outcomes between the baseline and follow-up periods.
We followed the most up-to-date SQUIRE (Standards for Quality Improvement Reporting 
Excellence) publication guidelines (Version 2.0) in reporting our study (Ogrinc et al. 2015).
Ethical considerations
The four key moral principles in conducting ethically sound research - autonomy, beneficence, 
non-maleficence, and justice (Beauchamp and Childress 2008), formed the ethical foundations 
of this study. All efforts to uphold the dignity of participants, to preserve their anonymity, 
confidentiality and protection against psychological harm were implemented through data 
collection, management and storage. Permission to access the database containing patient 
information was approved by the institutional review board (IRB) of the Dignity Health System 
(Ref #: 010764). The data within Midas was already de-identified. However, for data that 
needed to be collected outside Midas, only the principal researcher had access to patient names. 
The combined database created did not include any attributable data to the included patients. 
The data was secured on the researchers’ computers, was password protected and was not 
stored in any online/cloud storage.
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Results
One hundred and eighty-nine women met the inclusion criteria for this study, with 93 women 
included in the baseline period (before the initiative) and 96 women included in the follow-up 
period. Of the 93 women in the baseline group, 70 (75%) had been classified as obese while 63 
(66%) of the 96 women in the follow-up group had been classed obese (p=0.15) (Table I). 
Fifteen (16%) and 21 (22%) women in the baseline and follow-up group respectively had pre-
existing chronic hypertension by the time of hospitalisation (p=0.32) (Table I).
Regarding the pregnancy, 2 (2%) and 5 (5%) in the baseline and follow-up group respectively 
were pregnant with more than one foetus (p=0.27) (Table I). While 43 (46%) in the baseline 
and 50 (52%) in the follow-up group were term (37 weeks 0, as defined by the American 
College of Obstetrics and Gynaecology (ACOG Committee on Obstetric Practice Society of 
Maternal-Fetal Medicine 2013)) at the time of admission (p=0.42) (Table I). At delivery, 52 
(56%) and 59 (62%) were delivered by Caesarean in the baseline and follow-up arm of the 
study, respectively (p=0.44) (Table I).
There was no significant difference in the pre-eclampsia complications between the baseline 
and follow-up, except for stillbirth (p=0.027) (Table II). In a multivariate analysis, there was an 
87% (95%CI 0.06–0.92; p=0.027) decrease in the odds of having a stillbirth in the follow-up 
phase compared to the baseline (Table III). When adjusted for obesity, the adjusted odds ratio 
was estimated at 0.11 (95%CI 0.13–0.88; p=0.027) (Table III).
For the continuous variables, though the mean cost of hospitalisation was about $14 higher, this 
was not statistically significant (Table IV). Similarly, there was no statistically significant 
difference in admission-delivery and admission-discharge periods (Table IV). However, there 
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was a significant difference in duration of follow-up appointment following discharge (p<0.01), 
with mean days being estimated as approximately 13 and 7 days respectively for baseline and 
follow-up periods (Table IV).
Discussion
In this quasi-experimental study, we evaluated the effectiveness of the CMQCC preeclampsia 
treatment initiative on patient costs and outcomes. Our findings showed that in a tertiary 
hospital setting, there was no significant difference in maternal health outcomes. However, 
there was a significant difference in newborn health outcomes with almost 90% reduction in 
odds of babies being born as stillbirths following the uptake of the initiative compared with 
baseline. There was also a significant reduction in the number of days between discharge and 
follow-up appointments. Regarding the care costs, similarly, there was no significant change in 
cost after the initiative was implemented. As in other collaborative assessments (Main et al. 
2017), the groups used in this study for the baseline and follow-up periods were comparable as 
there was no significant difference in pregnancy characteristics and pre-existing conditions.
In a previous evaluation of the initiative, the authors found that compliance with utilisation of 
intravenous blood pressure medication increased by 33.2% (p<0.01) and utilisation of 
Magnesium Sulphate increased by 10.8% (p<0.01) during the six months of monitoring 
following the implementation of the initiative. In addition, incidence of eclampsia and total 
severe maternal morbidity (SMM) decreased by 42.6% (p<0.01) and 1.7% (p<0.01) 
respectfully (Shields et al. 2017). The former outcome change is a ‘process’ outcome, while the 
latter is a clinical outcome. While process outcomes demonstrate the evidence-based best 
practices that represent a health system’s efforts to systematise its improvement efforts, clinical 
outcomes represent the changes that patient’s experience (Mant 2001; Rademakers et al. 2011). 
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Both have their value, however, indicators for tracking clinical outcome can be particularly 
useful in standardised data collection methods and when the occurrence of the outcome is 
sufficiently common that the outcome indicator will have the power to detect real differences in 
quality (Mant 2001). While standardised data collection procedures were instituted in this 
study, the outcome did not occur sufficiently enough to allow our analyses to pick the “real” 
differences. For example, we found no statistically significant differences in maternal outcomes 
that occurred before and after the initiative. While this may be due to the high standard of care 
expected in a tertiary hospital such as the one evaluated in this study, it could also be because 
of the relatively small sample size, especially as an earlier study conducted on a larger scale 
showed significant differences in SMM before and after the initiative was implemented 
(Shields et al. 2017). As such, the null difference finding in our study needs to be interpreted 
with caution. However, our study clearly showed that the initiative had been fully embedded in 
the hospital with a highly significant reduction in the number of days between discharge and 
follow-up visits comparing the number of days women had to wait for follow-up appointments 
before and after the initiative (p<0.01). This is a process indicator that demonstrates uptake of 
the initiative within the facility.
One of the findings that had not been previously reported in the literature was a significant 
reduction in stillbirths in the follow-up period compared with the baseline. This significant 
reduction remained even after controlling for obesity. Pre-eclampsia is firmly associated with 
stillbirth (Conde-Agudelo et al. 2000; Ananth and Basso 2010; Smith 2015) and as evidenced 
in this study, clear guidelines in treating patients with the condition help to reduce associated 
mortalities with the unborn child. 
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One other key finding the absence of a cost difference between the baseline and follow-up 
periods. As such, the benefits of the initiative are not coming at a significant cost to the 
patients. In our study, we estimated costs at $1,589.23 at baseline and $1,607.36 during the 
Follow-up. A previous estimate of the short-term costs associated with pre-eclampsia per birth 
at 36 weeks of gestational age were at $1,311.00 (Stevens et al. 2017). As the study was based 
on data from 2012 (Stevens et al. 2017) and our study was based on data from the 2015 – 2016 
period, it is possible to attribute the observed difference to inflation.
One of the key strengths of this study was that it leveraged a robust electronic health system 
that had standardised obstetric data definitions (Menard et al. 2014). While this study offers 
unique insight regarding the effectiveness of the CMQCC quality initiative, it is important to 
recognise the limitations that we have identified. We did not collect race/ethnicity data, 
especially as the impact of race/ethnicity on hypertensive diseases of pregnancy (Fridman et al. 
2014). Furthermore, this study was based in a tertiary hospital. While facility based 
assessments like this provide some unique insight for quality improvement (Callaghan et al. 
2014), there may be different explanations as to why there are observed variations in obstetric 
services in different levels of care (Main 2015). With the singular facility assessed, there was 
also a limit to the sample size that could be achieved in the study. There is certainly a case for 
conducting this research on a larger scale while capturing more facilities including different 
levels of care facilities. This would allow for more study power to assess effect of confounders.
Conclusion
Scaling-up the uptake of the CMQCC quality improvement initiative in health facilities is a 
worthwhile venture, as along with its already evidenced effect on improving maternal health 
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outcomes in larger scale studies, we found that it contributes to reduction in stillbirths. These 
outcomes are achieved at no increase in hospitalisation cost for women with preeclampsia.
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Table I. Characteristics of pregnancy and pre-existing conditions
 Baseline (n=93) Follow-up (n=96) p value
Obesity 70 (75.3%) 63 (65.6%) 0.15
Chronic hypertension 15 (16.1%) 21 (21.9%) 0.32
Multiple gestation 2 (2.2%) 5. (5.2%) 0.27
Term pregnancy 43 (46.2%) 50 (52.1%) 0.42
Caesarean delivery 52 (56.0%) 59 (61.5%) 0.44
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Table II. Bivariate analysis of categorical outcome data
Outcome Total (N=189) Before After p value
Readmission     
Yes 13 6 (6.5%) 7 (7.3%) 0.820
No 176 87 (93.5%) 89 (92.7%)
Eclampsia     
Present 3 2 (2.2%) 1 (1.0%) 0.542
Not present 186 91 (97.8%) 95 (99.0%)
Cerebro-vascular accident    
Present 1 0 (0.0%) 1 (1.0%) 0.324
Not present 188 93 (100.0%) 95 (99.0%)
Post-partum haemorrhage    
Present 23 11 (11.8%) 12 (12.5%) 0.888
Not present 166 82 88.2%) 84 (87.5%)
Acute kidney injury    
Present 7 2 (2.2%) 5 (5.2%) 0.266
Not present 182 91 (97.8%) 91 (94.8%)
Liver injury     
Present 27 13 (13.9%) 14 (14.6%) 0.905
Not present 162 80 (86.0%) 82 (85.4%)
Birth status     
Still birth* 8 7 (7.5%) 1 (1.0%) 0.027
Live birth 181 86 (92.5%) 95 (99.0%)  
*Significant variable p<0.05
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Table III. Logistic regression analysis
Outcome
Crude odds ratio 
with 95% CI p value
Adjusted odds ratio 
with 95% CI p value
Readmission    
Yes - - -
No - - -
Eclampsia    
Present - - -
Not present - - -
Cerebro-vascular accident   
Present - - -
Not present - - -
Post-partum haemorrhage   
Present - - -
Not present - - -
Acute kidney injury    
Present - - -
Not present - - -
Liver injury    
Present - - -
Not present - - -
Birth status    
Still birth 0.13 (0.06–0.92) 0.03 0.11 (0.13–0.88) 0.04
Live birth 1.00 1.00
Table IV. Two-sample t test with equal variances for continuous variables
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Variable Group Mean Std. Error Std. Dev  [95% Conf. Interval] p value
Baseline 1,589.23 68.36 659.22 1453.47 1724.99 0.8323Hospitalisation 
cost Follow-up 1,607.36 51.91 508.60 1504.31 1710.41
Baseline 3.14 0.14 1.37 2.86 3.42 0.3142Admission to 
delivery period 
differentials Follow-up 3.34 0.14 1.41 3.05 3.63
Baseline 4.66 0.25 2.43 4.15 5.16 0.3542Admission to 
discharge period 
differentials Follow-up 4.99 0.26 2.5 4.48 5.59
Baseline 13.19 1.16 11.17 10.89 15.49 0.0000Follow-up 
appointment 
from discharge 
differentials* Follow-up 6.84 0.38 3.72 6.09 7.59  
Cost in US$. All women included in the analysis (93 at baseline and 96 at follow-up).
*Significant variable p<0.05
Page 22 of 23
URL: http:/mc.manuscriptcentral.com/cjog  Email: ianmartinsymonds@gmail.com
Journal of Obstetrics and Gynaecology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Supplemental material 1. ICD-10 codes included in analysis
Codes Description of condition
11.1 Pre-existing hypertension with pre-eclampsia, first trimester
11.2 Pre-existing hypertension with pre-eclampsia, second trimester
11.3 Pre-existing hypertension with pre-eclampsia, third trimester
11.9 Pre-existing hypertension with pre-eclampsia, unspecified trimester
14.1 Severe pre-eclampsia, unspecified trimester
14.12 Severe pre-eclampsia, second trimester
14.13 Severe pre-eclampsia, third trimester
14.2 HELLP syndrome, unspecified trimester
14.22 HELLP syndrome, second trimester
14.23 HELLP syndrome, third trimester
15 Eclampsia in pregnancy, unspecified trimester
15.02 Eclampsia in pregnancy, second trimester
15.03 Eclampsia in pregnancy, third trimester
15.1 Eclampsia in labour
15.2 Eclampsia, in the puerperium
15.9 Eclampsia, unspecified as to time period
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